NCT07026318 Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke
| NCT ID | NCT07026318 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Anzhen Hospital |
| Condition | Acute Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 716 participants |
| Start Date | 2025-08-15 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 716 participants in total. It began in 2025-08-15 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to evaluate whether adjunctive tirofiban therapy combined with endovascular treatment (EVT) improves neurological outcomes in patients with acute large vessel occlusion due to large-artery atherosclerosis. Patients will be randomized to receive either tirofiban or matching placebo after EVT. The primary efficacy endpoint is the proportion of patients achieving functional independence (modified Rankin Scale 0-2) at 90±7 days, while the safety endpoint is the probability of symptomatic intracranial hemorrhagewithin 48 hours after randomization.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years 2. Pre-stroke modified Rankin Scale (mRS) score of 0-1 3. Acute ischemic stroke symptoms present within 24 hours of last known well time 4. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6 5. Anterior circulation: Alberta Stroke Program Early CT Score (ASPECTS) ≥6 Posterior circulation: pc-ASPECTS ≥6 6. Occlusion of intracranial internal carotid artery (ICA), M1 segment of middle cerebral artery (MCA), V4 segment of vertebral artery, or basilar artery 7. Clinical care team plans to perform endovascular thrombectomy (EVT) 8. Subject or legally authorized representative can provide informed consent 9. Residual stenosis ≥50% without planned angioplasty/stenting Exclusion Criteria: 1. Intracranial hemorrhage confirmed by imaging prior to randomization, or major intracranial hemorrhage on intraprocedural flat-panel CT 2. Gastrointestinal or genitourinary bleeding within 30 days post-stroke onset, or major surgery within 14 days 3. Bleeding diathesis including coagulopathy (platelets \<100×10⁹/L, aPTT \>50s, or INR \>2.0), DOAC use within 48 hours, or history of HIT 4. Pregnancy or lactation at admission 5. Contraindications to radiographic contrast agents, nickel, titanium or their alloys 6. Life expectancy \<6 months 7. Pre-existing neurological/psychiatric conditions that may confound assessment 8. Severe renal insufficiency (GFR \<30mL/min or Scr \>220μmol/L \[2.5mg/dL\]) 9. Arterial tortuosity or anomalies preventing device delivery 10. Unlikely to complete 90-day follow-up 11. Any confirmed cardioembolic source (including atrial fibrillation, valvular disease, intracardiac thrombus, recent MI, cardiomyopathy with EF \<30%, etc.) 12. Tirofiban or other GP IIb/IIIa inhibitor use before randomization or other GP IIb/IIIa inhibitor used post treatment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07026318 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07026318 currently recruiting?
Yes, NCT07026318 is actively recruiting participants. Contact the research team at hxc810909@163.com for enrollment information.
Where is the NCT07026318 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07026318 clinical trial?
NCT07026318 is sponsored by Beijing Anzhen Hospital. The trial plans to enroll 716 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.